GSK receives breakthrough status for new monthly liver disease drug

In April 2026, GSK reached a significant milestone in medical research as their investigational drug, efimosfermin, received Breakthrough Therapy Designation from the FDA and PRIME status from the EMA.

This regulatory support aims to speed up the development of a potential new treatment for Metabolic Dysfunction-Associated Steatohepatitis (MASH), a serious liver condition that affects about 5% of the global population.

MASH is a progressive disease that causes liver inflammation and scarring, or fibrosis, often leading to liver failure or cancer.

By regulating metabolic pathways, it helps reduce liver fat and reverse fibrosis.

Notably, it is designed as a convenient once-monthly subcutaneous injection.

Positive Phase II clinical trial data showed that the drug significantly improved fibrosis and resolved MASH, with only mild side effects reported.

The drug is currently in Phase III trials, known as ZENITH-1 and ZENITH-2, marking a promising step forward for patients suffering from moderate-to-advanced liver fibrosis who are waiting for effective therapies.